Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Abstract

A safe, effective, and scalable vaccine is urgently needed to halt the ongoing SARS-CoV-2 pandemic. Here, we describe the structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice. The nanoparticle vaccines display 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly immunogenic array and induce neutralizing antibody titers roughly ten-fold higher than the prefusion-stabilized S ectodomain trimer despite a more than five-fold lower dose. Antibodies elicited by the nanoparticle immunogens target multiple distinct epitopes on the RBD, suggesting that they may not be easily susceptible to escape mutations, and exhibit a significantly lower binding:neutralizing ratio than convalescent human sera, which may minimize the risk of vaccine-associated enhanced respiratory disease. The high yield and stability of the protein components and assembled nanoparticles, especially compared to the SARS-CoV-2 prefusion-stabilized S trimer, suggest that manufacture of the nanoparticle vaccines will be highly scalable. These results highlight the utility of robust antigen display platforms for inducing potent neutralizing antibody responses and have launched cGMP manufacturing efforts to advance the lead RBD nanoparticle vaccine into the clinic.

Full text

Its licence does not allow us to show the full text. Read it at PubMed Central:

References 99

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.4049/jimmunol.2000583

2. 2.
   Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus · 2017

   No notice
3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1093/infdis/jiz070

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1126/science.aaf8818

5. 5.
   Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies · 2020

   No notice
6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.
   Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle · 2019

   No notice
8. 8.
   Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020

   No notice
9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1021/acsnano.8b02805

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-020-2622-0

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1073/pnas.1510199112

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.cell.2020.06.035

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1128/jvi.00859-18

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41594-020-00547-5

16. 16.
    An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates · 2020

    No notice
17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/s0140-6736(20)31604-4

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/nmeth.1318

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1002/pro.3235

20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1126/science.abb8923

21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1007/s13361-013-0727-5

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41594-020-0479-4

23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.cell.2020.02.052

24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.cell.2020.05.042

25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/nature18010

26. 26.
    Structure-based design of prefusion-stabilized SARS-CoV-2 spikes · 2020

    No notice
27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.chom.2020.07.002

28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.coi.2020.01.007

29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1056/nejmoa2022483

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.cell.2015.07.043

31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1093/infdis/jiy745

32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1101/cshperspect.a038448

33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41590-018-0305-x

34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/nature12202

35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1056/nejmoa2026920

36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1093/oxfordjournals.aje.a120955

37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1126/science.1219364

38. 38.
    Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis · 2018

    Corrected
39. 39.
    Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies · 2018

    No notice
40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.chroma.2013.10.087

41. 41.
    Somatically Hypermutated Plasmodium-Specific IgM+ Memory B Cells Are Rapid, Plastic, Early Responders upon Malaria Rechallenge · 2016

    No notice
42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.biologicals.2014.05.007

43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-020-2180-5

44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/nbt.2825

45. 45.
    Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin · 2019

    No notice
46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41564-020-0688-y

47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/nature02145

48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1002/jmv.25701

49. 49.
    Self-assembling protein nanoparticles in the design of vaccines · 2015

    No notice
50. 50.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.xcrm.2021.100252

51. 51.
    Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus · 2019

    No notice
52. 52.
    Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation · 2020

    No notice
53. 53.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/nm.3985

54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1073/pnas.1517719113

55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.21769/bioprotoc.2035

56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1073/pnas.1707304114

58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-020-2349-y

59. 59.
    Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients · 2020

    No notice
60. 60.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1084/jem.20020781

61. 61.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-020-2456-9

62. 62.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1128/jvi.02377-07

63. 63.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1128/jvi.72.1.497-503.1998

64. 64.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

65. 65.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.immuni.2020.06.001

66. 66.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-020-2179-y

67. 67.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1146/annurev-virology-031413-085507

68. 68.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1126/science.aaf8505

69. 69.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1084/jem.20112272

70. 70.
    Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants · 2006

    No notice
71. 71.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/bs.aivir.2019.08.002

72. 72.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/nm1080

73. 73.
    Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens · 2020

    No notice
74. 74.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1128/jvi.01351-16

75. 75.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.cell.2020.02.058

76. 76.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/nature16988

77. 77.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/nsmb.3293

78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1073/pnas.1708727114

79. 79.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.cell.2018.12.028

80. 80.
    A human monoclonal antibody blocking SARS-CoV-2 infection · 2020

    Corrected
81. 81.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.cell.2020.03.045

82. 82.
    Site-specific glycan analysis of the SARS-CoV-2 spike · 2020

    No notice
83. 83.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.jasms.2006.07.025

84. 84.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.virol.2006.02.041

85. 85.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1126/science.abb2507

86. 86.
    A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 · 2020

    No notice
87. 87.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41594-020-0478-5

88. 88.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1128/jvi.01628-17

89. 89.
    Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 · 2020

    No notice
90. 90.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1128/jvi.01279-15

91. 91.
    DNA vaccine protection against SARS-CoV-2 in rhesus macaques · 2020

    No notice
92. 92.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1126/science.abb7269

93. 93.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1021/ac300535r

94. 94.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41594-020-0480-y

95. 95.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.cub.2020.05.023

96. 96.
    A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

    No notice
97. 97.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/s0140-6736(20)31208-3

98. 98.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1056/nejmoa2001017

99. 99.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-020-2548-6

Cited by papers we hold 23

• Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment · 2024
  No notice
• De novo design of protein structure and function with RFdiffusion · 2023
  No notice
• Vaccine adjuvants: mechanisms and platforms · 2023
  No notice
• Current approaches of nanomedicines in the market and various stage of clinical translation · 2022
  Not checked
• mRNA-based therapeutics: powerful and versatile tools to combat diseases · 2022
  No notice
• Robust deep learning–based protein sequence design using ProteinMPNN · 2022
  No notice
• COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection · 2022
  No notice
• COVID-19 vaccine development: milestones, lessons and prospects · 2022
  No notice
• Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases · 2022
  No notice
• Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models · 2022
  No notice
• Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines · 2022
  No notice
• A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections · 2021
  Not checked
• Pore-forming alpha-hemolysin efficiently improves the immunogenicity and protective efficacy of protein antigens. · 2021
  Not checked
• Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice · 2021
  No notice
• Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection · 2021
  No notice
• SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern · 2021
  No notice
• A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses · 2021
  No notice
• Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies · 2021
  Corrected
• Protein-based antigen presentation platforms for nanoparticle vaccines · 2021
  No notice
• Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 · 2021
  No notice

and 3 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.